Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine vs N-acetylcysteine for methamphetamine craving reduction
IRCT20240924063151N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of atomoxetine and acetylcysteine in methamphetamine use disorder (MUD) (2 arms), sponsored by Arak University of Medical Sciences. Started Nov 2024; status: completed.
02
Drugs
atomoxetineacetylcysteine
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on IRCT20240924063151N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240924063151N1.